News
News Flash: Memory Shop and Anime Zakka to Open in Harvard Square
News
Harvard Researchers Develop AI-Driven Framework To Study Social Interactions, A Step Forward for Autism Research
News
Harvard Innovation Labs Announces 25 President’s Innovation Challenge Finalists
News
Graduate Student Council To Vote on Meeting Attendance Policy
News
Pop Hits and Politics: At Yardfest, Students Dance to Bedingfield and a Student Band Condemns Trump
The majority of critically ill COVID-19 patients survive under current treatment guidelines for respiratory failure, clinicians at two Harvard teaching hospitals found.
The team of doctors — led by Massachusetts General Hospital pulmonologist and Harvard Medical School professor Charles C. Hardin — announced the findings in a press release Wednesday after publishing their research in the peer-reviewed American Journal of Respiratory and Critical Care Medicine.
In the study, the nine-person team monitored and treated 66 critically ill and intubated COVID-19 patients at MGH and Beth Israel Deaconess Medical Center for more than two weeks.
The most severe COVID-19 cases can result in a condition known as Acute Respiratory Distress Syndrome, a type of life-threatening respiratory failure causing excess fluid buildup in the lung’s air sacs, the researchers found. They treated these patients with guideline-supported protocols for ARDS respiratory failure.
The death rate among COVID-19 patients treated under those ARDS protocols was 16.7 percent — which is lower than the rate reported by other hospitals, according to the press release. In intensive care units, 75.8 percent of patients on mechanical ventilators were discharged after a median follow-up time of just over a month.
“The good news is we have been studying ARDS for over 50 years and we have a number of effective evidenced-based therapies with which to treat it,” Hardin said in the press release. “We applied these treatments — such as prone ventilation where patients are turned onto their stomachs — to patients in our study and they responded to them as we would expect patients with ARDS to respond.”
As hospitals worldwide have shared anecdotal and one-off treatment strategies, the findings point to a more robust treatment strategy for critically ill COVID-19 patients, according to the release.
“Based on this, we recommend that clinicians provide evidence-based ARDS treatments to patients with respiratory failure due to COVID-19 and await standardized clinical trials before contemplating novel therapies,” Medical School instructor and study co-author Jehan Alladina said in the press release.
—Staff writer Simon J. Levien can be reached at simon.levien@thecrimson.com. Follow him on Twitter @simonjlevien.
Want to keep up with breaking news? Subscribe to our email newsletter.